Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03823391 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

A Phase 2 study of Rheumatoid Arthritis (RA), sponsored by AbbVie.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
20
Study locations

NCT03823391 is a Phase 2 study of Rheumatoid Arthritis (RA) that has completed, run by AbbVie. The registered enrollment target is 48 participants, below the 265-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03823391, a Phase 2 study of Rheumatoid Arthritis (RA), has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

Conditions Studied

Rheumatoid Arthritis (RA)

Interventions

  • DRUG Adalimumab
  • DRUG ABBV-3373
  • DRUG Placebo for ABBV-3373
  • DRUG Placebo for adalimumab

Study Locations (20)

Florida

  • Suncoast Clinical Research /ID# 213973 - New Port Richey
  • Arthritis Center, Inc. /ID# 213972 - Palm Harbor
  • W. Broward Rheum Assoc Inc. /ID# 211017 - Tamarac
  • BayCare Medical Group, Inc. /ID# 213935 - Tampa

California

  • C.V. Mehta MD, Med Corporation /ID# 213068 - Hemet
  • Robin K. Dore MD, Inc /ID# 213045 - Tustin
  • Inland Rheum & Osteo Med Grp /ID# 213044 - Upland

Ohio

  • Paramount Medical Research Con /ID# 209042 - Middleburg Heights
  • STAT Research, Inc. /ID# 213933 - Vandalia

Texas

  • PCCR Solution /ID# 215457 - Colleyville
  • Trinity Universal Research Association /ID# 209167 - Plano

Alabama

  • Rheum Assoc of North Alabama /ID# 213626 - Huntsville

Arizona

  • AZ Arthritis and Rheum Researc /ID# 208515 - Phoenix

Idaho

  • Institute of Arthritis Researc /ID# 213043 - Idaho Falls

Kansas

  • PRN Professional Research Network of Kansas, LLC /ID# 213046 - Wichita

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2019-03-27
Est. Completion 2020-08-26
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03823391

The ClinicalTrials.gov registry entry for NCT03823391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 265-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (82% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 4 interventions - of which Adalimumab is the first listed.

NCT03823391 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT03823391 about?

NCT03823391 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)". This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

What is the current status of trial NCT03823391?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-03-27. Estimated completion is 2020-08-26.

What conditions does trial NCT03823391 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis (RA).

What interventions are being tested in trial NCT03823391?

The interventions under investigation include: Adalimumab (DRUG), ABBV-3373 (DRUG), Placebo for ABBV-3373 (DRUG), Placebo for adalimumab (DRUG).

Who is sponsoring clinical trial NCT03823391?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03823391 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis (RA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis (RA)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.